RT Journal Article
SR Electronic
T1 Serum responses of children with Kawasaki Disease against SARS-CoV-2 proteins
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.24.20111732
DO 10.1101/2020.05.24.20111732
A1 Arthur J Chang
A1 Michael Croix
A1 Patrick Kenney
A1 Sarah Baron
A1 Mark D Hicar
YR 2020
UL http://medrxiv.org/content/early/2020/05/26/2020.05.24.20111732.abstract
AB Recently, numerous reports have suggested association of pediatric Coronavirus Disease 2019 (COVID-19) cases and Kawasaki Disease (KD). KD is a major cause of childhood acquired heart disease and vasculitis in the pediatric population. Epidemiological patterns suggest KD is related to an infectious agent; however, the etiology remains unknown1. As past reports have considered other coronaviruses to be related to KD2,3, these reports of pediatric COVID-19 related inflammatory disorder cases leads to the hypothesis of potential cross-coronavirus reactivity that would account for the past controversial proposals of other coronaviruses and these new cases. We sought to address this hypothesis by assessing the antigen targeting of biobanked plasma samples of febrile children, including those with KD, against SARS-CoV-2 proteins.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis was supported by SUNY Research Seed Grant Program 2019-2020 and by the Wildermuth Foundation through the Variety Club of Buffalo.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University at Buffalo IRB approved sample collection for COVID-19 (STUDY00004340) and Kawasaki disease MODCR00000185.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData available by contacting author.